In the News



NeuroRx aims to tackle suicide by treating bipolar depression with new therapy

Christine Corrado

Proactive Investors View the Interview

May 8, 2019

© 2020 NeuroRx, Inc.

*These drugs are investigational and not approved by the US FDA


Suicide is a national epidemic. We need to treat it like one.

Jonathan C Javitt, MD, MPH


Op-ed, Washington Post View Article

Jul 5, 2018

NeuroRx Receives Special Protocol Agreement (SPA) and Biomarker Letter of Support from FDA for Pivotal Studies of NRX-101 to treat Severe Bipolar Depression in Patients with Acute Suicidal Ideation & Behavior


FirstWord Pharma View Article

May 7, 2018

Collaboration to address clinical trial of first drug regiment for ASIB


Page 7, Mental Health Weekly View Article

Jan 1, 2018

"NeuroRx - Developing Treatment for Acute Suicidal Ideation/Behavior (ASIB) in Bipolar Depression"
Dr. Jonathan Javitt, CEO of NeuroRx, on Small Cap Nation

Nov 7, 2017

The K factor:

How the party drug ketamine may hold the key to treating patients with severe depression

Nina Notman, Chemistry World


View Article

March 4, 2017

Funding for Psychiatric Drugs Growing Scarce

The Hill


View Article

November 8, 2016

Dr. Jonathan Javitt, CEO of NeuroRx, on ILTV News

June 19, 2016

Special Report on NeuroRx, Cyclurad, and an exclusive interview with Dr. Jonathan Javitt, CEO of NeuroRx,

Israel's Channel 2 News

July 2015

Anti-suicide drug wins praise at IATI-Biomed 2016

Israel 21c


View Article

June 1, 2016

Israeli Company Offers New Hope for Treating Severe Depression

Globes: Israel's Business Arena


View Article

New Drug Combo involving Ketamine Shows Promise for Bipolar Depression

Psychiatry Advisor


View Article

July 1, 2015

June 25, 2015

June 24, 2015

June 24, 2015

Study: Drug Combination Offers Hope for Bipolar Depression

USA Today


View Article

Study Shows Drug Combination Can Treat Bipolar Depression



View Article

How NeuroRx Pharma is Turning Suicidal Ideation Into A Treatable Condition

David Rich, Market Exclusive


View Article

November 30, 2016